Company: DHR
Filing Date: 2025-07-22
Form Type: 10-Q
Source: 0000313616-25-000153
Chunk: 45

Company: DANAHER CORP /DE/
Filing Date: 2025-07-22
Form: 10-Q
Item: Item 1
Chunk 45
---
4 operating profit margin comparisons were favorably impacted by:

•First half of 2024 acquisition-related fair value adjustment to inventory - 70 basis points

Depreciation and amortization of intangible assets increased as a percentage of sales during both the three and six-month periods ended June 27, 2025, primarily as a result of the decrease in sales and the impact of acquisitions.  

DIAGNOSTICS

The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

Diagnostics Selected Financial Data

 Three-Month Period EndedSix-Month Period Ended($ in millions)June 27, 2025June 28, 2024June 27, 2025June 28, 2024Sales$2,309 $2,260 $4,758 $4,787 Operating profit554 556 1,272 1,386 Depreciation100 100 200 197 Amortization of intangible assets48 48 96 96 Operating profit as a % of sales24.0 %24.6 %26.7 %29.0 %Depreciation as a % of sales4.3 %4.4 %4.2 %4.1 %Amortization as a % of sales2.1 %2.1 %2.0 %2.0 %

Sales Growth (Decline) and Core Sales Growth

% Change Three-Month Period Ended June 27, 2025 vs. Comparable 2024 Period% Change Six-Month Period Ended June 27, 2025 vs. Comparable 2024 PeriodTotal sales growth (decline) (GAAP)2.0 %(0.5)%Impact of:Divestitures0.5 %0.5 %Currency exchange rates (0.5)%— %Core sales growth (non-GAAP)2.0 %— %

Price decreases in the segment of 1.0%, attributable to factors discussed below, negatively impacted the year-over-year change in sales during both the three and six-month periods ended June 27, 2025 and are reflected as a component of core sales above.

Total segment sales increased 2.0% during the three-month period primarily as a result of increased core sales and to a lesser